Hospital officials throughout the United States are being asked to assess antithrombotic therapy. The Institute for Safe Medication Practices (ISMP) Medication Safety Self-Assessment for Antithrombotic Therapy in Hospitals will help health care organizations examine medication-safety practices associated with prescribing, dispensing, administration, and monitoring of therapy in their facilities. The participants will review 125 different characteristics that considerably impact medication safety when patients receive antithrombotic medications, including anticoagulants and thrombolytic agents.
As with previous ISMP self-assessment surveys, hospitals are being asked to assemble multidisciplinary teams to participate and provide a range of perspectives. Institution officials are encouraged to submit their data through a secure Web-based form, which will allow them to compare their weighted scores with aggregate data from other demographically similar hospitals. The deadline for data submission is September 1, 2005. Collected data are scheduled to be released in early 2006 and will be used to support ISMP's medication-safety efforts.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs